Cardiotoxicity of chemotherapeutic agents
Cardiology Chemotherapy
Nova Science Publishers
2017
EISBN 9781536121353
Preface; Chapter 1; Introduction: Cardiotoxicity of Chemotherapeutic Agents; Introduction; References; Chapter 2; Alkylating Agents; Cyclophosphamide; Ifosphamide (IFS); Carboplatin; Busulfan; Altretamine (Hexalen); Procarbazine; References; Chapter 3; Antimetabolites; 5-Fluorouracil; Raltitrexed (Tomudex); Cytosine Arabinoside (Cytarabine or Ara-C); Gemcitabine; Pentostatin; Other Antimetabolites; References; Chapter 4; Antitumor Antibiotics: Bleomycin and Mitoxantrone; Bleomycin; Mitoxantrone; References; Chapter 5
Antitumor Antibiotics: Newer AnthracyclinesNew Anthracyclines; References; Chapter 9; Microtubule Inhibitors; Microtubule Inhibitors; Paclitaxel; Docetaxel; Vinca Alkaloids; Eribulin; Ixabepilone; References; Chapter 10; Hormonal Therapy; Estrogens; Aromatase Inhibitors; Progestins; Tamoxifen; Androgen Deprivation Therapy; Flutamide; Leuprolide; Cyproterone Acetate; References; Chapter 11; Immunotherapy; Interleukin; Interferon; References; Chapter 12; Monoclonal Antibodies; Trastuzumab; Rituximab; Alemtuzumab; Bevacizumab; Cetuximab; Gemtuzumab; Ibritumomab; Tositumomab; References
Chapter 13Tyrosine Kinase Inhibitors; Imatinib; Dasatinib; Nilotinib; Sunitinib; Sorafenib; Lapatinib; Erlotinib and Geftinib; Other Tyrosine Kinase Inhibitors; References; Chapter 14; Topoisomerase-1 Inhibitors and Miscellaneous Drugs; Topoisomerase-1 Inhibitors; Irinotecan (CAMPTOSAR) and Topotecan (Hycamtin); Other Miscellaneous Drugs; Tretinoin; Arsenic Trioxide (Trisenox); References; About the Editors; Index; Blank Page
Antitumor Antibiotics: Anthracyclines, a Mechanism of CardiotoxicityAnthracyclines (Daunorubicin and Doxorubicin); Mechanisms of Anthracycline Toxicity; i. Reactive Oxygen Species and Redox Cycling; ii. Calcium Exchange Channels; iii. Role of GATA4; iv. Changes in Endogenous Adaptive Reserve of the Heart; v. Role of Topoisomerase 2β; vi. Role of Neuregulin-1, ErbB2, and ErbB4 Signalling; References; Chapter 6; Antitumor Antibiotics: Anthracyclines, Cardiotoxicity and Associated Risk Factors; Cardiotoxicity Caused by Anthracyclines
I. Electrocardiogram (EGC) Changes and Arrhythmias Associated with Anthracycline Useii. Chronic Cardiomyopathy; iii. Sub-Clinical Cardiotoxicity; Risk Factors Associated with Poor Long-Term Cardiovascular Outcomes; References; Chapter 7; Antitumor Antibiotics: Anthracyclines and Minimizing Cardiotoxicity; Approaches to Minimize Anthracycline Cardiotoxicity; 1. Pharmacokinetic Approaches for Cardiac Prevention; 2. Pharmacogenetic Approaches for Cardiac Prevention; 3. Chemo Protectants and Adjunctive Therapies to Reduce Cardiotoxicity; References; Chapter 8
Antitumor Antibiotics: Newer AnthracyclinesNew Anthracyclines; References; Chapter 9; Microtubule Inhibitors; Microtubule Inhibitors; Paclitaxel; Docetaxel; Vinca Alkaloids; Eribulin; Ixabepilone; References; Chapter 10; Hormonal Therapy; Estrogens; Aromatase Inhibitors; Progestins; Tamoxifen; Androgen Deprivation Therapy; Flutamide; Leuprolide; Cyproterone Acetate; References; Chapter 11; Immunotherapy; Interleukin; Interferon; References; Chapter 12; Monoclonal Antibodies; Trastuzumab; Rituximab; Alemtuzumab; Bevacizumab; Cetuximab; Gemtuzumab; Ibritumomab; Tositumomab; References
Chapter 13Tyrosine Kinase Inhibitors; Imatinib; Dasatinib; Nilotinib; Sunitinib; Sorafenib; Lapatinib; Erlotinib and Geftinib; Other Tyrosine Kinase Inhibitors; References; Chapter 14; Topoisomerase-1 Inhibitors and Miscellaneous Drugs; Topoisomerase-1 Inhibitors; Irinotecan (CAMPTOSAR) and Topotecan (Hycamtin); Other Miscellaneous Drugs; Tretinoin; Arsenic Trioxide (Trisenox); References; About the Editors; Index; Blank Page
Antitumor Antibiotics: Anthracyclines, a Mechanism of CardiotoxicityAnthracyclines (Daunorubicin and Doxorubicin); Mechanisms of Anthracycline Toxicity; i. Reactive Oxygen Species and Redox Cycling; ii. Calcium Exchange Channels; iii. Role of GATA4; iv. Changes in Endogenous Adaptive Reserve of the Heart; v. Role of Topoisomerase 2β; vi. Role of Neuregulin-1, ErbB2, and ErbB4 Signalling; References; Chapter 6; Antitumor Antibiotics: Anthracyclines, Cardiotoxicity and Associated Risk Factors; Cardiotoxicity Caused by Anthracyclines
I. Electrocardiogram (EGC) Changes and Arrhythmias Associated with Anthracycline Useii. Chronic Cardiomyopathy; iii. Sub-Clinical Cardiotoxicity; Risk Factors Associated with Poor Long-Term Cardiovascular Outcomes; References; Chapter 7; Antitumor Antibiotics: Anthracyclines and Minimizing Cardiotoxicity; Approaches to Minimize Anthracycline Cardiotoxicity; 1. Pharmacokinetic Approaches for Cardiac Prevention; 2. Pharmacogenetic Approaches for Cardiac Prevention; 3. Chemo Protectants and Adjunctive Therapies to Reduce Cardiotoxicity; References; Chapter 8
